Agenus Inc (AGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Agenus Inc (AGEN) has a cash flow conversion efficiency ratio of 0.152x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.20 Million) by net assets ($-205.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Agenus Inc stock valuation for the company's overall valuation and market capitalisation.
Agenus Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Agenus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Agenus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agenus Inc ranked by their cash flow conversion efficiency. Explore Agenus Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MGP Ingredients Inc
NASDAQ:MGPI
|
0.041x |
|
Bunker Hill Mining Corp.
V:BNKR
|
0.098x |
|
Fiverr International Ltd
F:11V
|
0.053x |
|
Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
NASDAQ:PSNYW
|
0.179x |
|
FIC Global Inc
TW:3701
|
0.088x |
|
Velos Acquisition I Corp.
NASDAQ:VLOS
|
-0.005x |
|
Hai An Transport and Stevedoring JSC
VN:HAH
|
0.071x |
|
TigerElec Co. Ltd
KQ:219130
|
0.051x |
Annual Cash Flow Conversion Efficiency for Agenus Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Agenus Inc from 1999 to 2025. View AGEN stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-277.86 Million | $-158.31 Million | 0.570x | +10.28% |
| 2024-12-31 | $-306.42 Million | $-158.31 Million | 0.517x | -65.81% |
| 2023-12-31 | $-148.38 Million | $-224.20 Million | 1.511x | -52.70% |
| 2022-12-31 | $-54.90 Million | $-175.37 Million | 3.194x | +1408.48% |
| 2021-12-31 | $47.91 Million | $10.14 Million | 0.212x | -67.80% |
| 2020-12-31 | $-211.50 Million | $-139.10 Million | 0.658x | +714.39% |
| 2019-12-31 | $-231.34 Million | $-18.68 Million | 0.081x | -89.25% |
| 2018-12-31 | $-174.55 Million | $-131.09 Million | 0.751x | -39.57% |
| 2017-12-31 | $-75.82 Million | $-94.23 Million | 1.243x | -39.19% |
| 2016-12-31 | $-39.13 Million | $-79.96 Million | 2.044x | +406.40% |
| 2015-12-31 | $70.73 Million | $-47.18 Million | -0.667x | +59.85% |
| 2014-12-31 | $23.02 Million | $-38.23 Million | -1.661x | -138.11% |
| 2013-12-31 | $-4.48 Million | $-19.53 Million | 4.359x | +5274.33% |
| 2012-12-31 | $-12.02 Million | $1.01 Million | -0.084x | -110.80% |
| 2011-12-31 | $-20.83 Million | $-16.25 Million | 0.780x | -22.26% |
| 2010-12-31 | $-14.71 Million | $-14.76 Million | 1.003x | -29.59% |
| 2009-12-31 | $-16.98 Million | $-24.19 Million | 1.425x | +17.91% |
| 2008-12-31 | $-23.92 Million | $-28.91 Million | 1.209x | +113.12% |
| 2007-12-31 | $-47.06 Million | $-26.69 Million | 0.567x | -78.05% |
| 2006-12-31 | $-17.39 Million | $-44.94 Million | 2.584x | +224.26% |
| 2005-12-31 | $31.90 Million | $-66.33 Million | -2.079x | -267.49% |
| 2004-12-31 | $106.44 Million | $-60.22 Million | -0.566x | -16.33% |
| 2003-12-31 | $105.25 Million | $-51.19 Million | -0.486x | +25.60% |
| 2002-12-31 | $77.76 Million | $-50.83 Million | -0.654x | -34.79% |
| 2001-12-31 | $75.92 Million | $-36.83 Million | -0.485x | -274.02% |
| 2000-12-31 | $116.70 Million | $-15.13 Million | -0.130x | +50.34% |
| 1999-12-31 | $51.70 Million | $-13.50 Million | -0.261x | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more